{
  "scenario_id": "pharmaceutical_companion_diagnostics_development_decision",
  "context": "Biopharmaceutical company developing targeted therapy requiring companion diagnostic for patient selection",
  "stakeholders": {
    "requester": "Chief Medical Officer",
    "approvers": [
      "Chief Executive Officer",
      "Chief Scientific Officer",
      "Board of Directors"
    ],
    "influencers": [
      "Regulatory Affairs Director",
      "Commercial Strategy VP",
      "Diagnostics Development Lead",
      "Clinical Operations Director"
    ]
  },
  "request": {
    "amount": "$12M",
    "purpose": "Develop and validate companion diagnostic test for precision medicine therapy",
    "urgency": "high",
    "justification": "Required for regulatory approval and market access of $800M therapy opportunity"
  },
  "decision_process": [
    {
      "stage": "scientific_validation",
      "duration": "8 weeks",
      "activities": [
        "Biomarker identification",
        "Assay development",
        "Analytical validation"
      ],
      "outcome": "Identified predictive biomarker with 90% sensitivity and specificity"
    },
    {
      "stage": "regulatory_strategy",
      "duration": "6 weeks",
      "activities": [
        "FDA consultation",
        "Regulatory pathway mapping",
        "Co-development planning"
      ],
      "outcome": "Aligned development timeline with therapeutic approval requirements"
    },
    {
      "stage": "commercial_assessment",
      "duration": "4 weeks",
      "activities": [
        "Market access analysis",
        "Pricing strategy",
        "Reimbursement planning"
      ],
      "outcome": "Projected $150M diagnostic revenue stream with therapy"
    },
    {
      "stage": "partnership_evaluation",
      "duration": "6 weeks",
      "activities": [
        "Diagnostic partner assessment",
        "Collaboration agreements",
        "IP arrangements"
      ],
      "outcome": "Strategic partnership with leading diagnostics company secured"
    }
  ],
  "business_impact": {
    "expected_outcome": "Essential companion diagnostic enabling $800M targeted therapy market access",
    "projected_value": "$200M NPV contribution to therapy franchise",
    "risk_factors": [
      "Regulatory delays in diagnostic approval",
      "Technical validation challenges",
      "Market adoption barriers"
    ]
  },
  "decision_criteria": [
    "Regulatory requirement fulfillment",
    "Scientific validity",
    "Commercial value",
    "Development feasibility",
    "Timeline alignment"
  ],
  "outcome": "Approved",
  "lessons_learned": "Early diagnostic development parallel to therapeutic crucial for precision medicine success"
}